|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The sphingosine-1-phosphate (S1P) receptor S1PR2 and its downstream adaptor Gα13 are recurrently mutationally inactivated in the germinal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL) and are silenced by the S1PR2 repressor FOXP1 in the activated B-cell like subtype of the disease.
|
31648327 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
FOXP1 is one of the critical transcription factors whose deregulated expression makes important contributions to DLBCL pathogenesis.
|
27678023 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, overexpression of full-length FOXP1 or this small FOXP1 isoform in primary B cells and diffuse large B-cell lymphoma cell lines resulted in similar gene regulation.
|
27909217 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of the activation markers Blimp1, Foxp1 and pStat3 in extranodal diffuse large B-cell lymphomas.
|
27924626 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In vivo studies using the transduced cell lines in mice enabled us to demonstrate a tumor suppressor effect of miR-92a and an oncogenic effect of FOXP1.A higher expression of miR-92a and the down-regulation of FOXP1 mRNA and protein expression were also found in human samples of PMBL, while miR-92a expression was low and FOXP1 was high in DLBCL.
|
27806315 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The ratio of FOXP1L:FOXP1S isoforms correlated with differential expression of plasmacytic differentiation markers in U-2932 subpopulations, and altering this ratio was sufficient to modulate CD19 expression in diffuse large B-cell lymphoma cell lines.
|
27056922 |
2016 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
FOXP2-positive DLBCL had reduced expression of HIP1R (P = 0.0348), which is directly repressed by FOXP1, and exhibited distinct patterns of gene expression.
|
27224915 |
2016 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cell-line derived FOXP1 target genes that were highly correlated with FOXP1 expression in primary DLBCL accurately segregated the corresponding clinical subtypes of a large cohort of primary DLBCL isolates and identified conserved pathways associated with ABC-DLBCL pathology.
|
26787899 |
2016 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We propose that FOXP1 represents a novel regulator of genes targeted by the class II MHC transactivator CIITA (MHC II and CD74) and therapeutically targeting the FOXP1 pathway may improve antigen presentation and immune surveillance in high-risk DLBCL patients.
|
26500140 |
2016 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling.
|
26729899 |
2016 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phenotypic studies with carefully selected biomarkers like CD5 and FOXP1 are able to prognosticate DLBCL course at diagnosis, independent of stage and IPI and independent of response to R-CHOP.
|
26071053 |
2015 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Finally, using FISH, we show that CIITA (8/82; 10%) and FOXP1 (5/74; 7%) rearrangements are recurrent in PTL.
|
25712539 |
2015 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FOXP1, p53, and BCL2 positivity was associated with poor OS with both lymphoma types but OS with DLBCL was significantly lower than with MALT lymphoma.
|
24232982 |
2014 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIP1R repression by FOXP1 is strongly associated with poor outcome, thus further understanding of FOXP1-HIP1R and/or endocytic signaling pathways might give rise to novel therapeutic options for DLBCL.
|
23884370 |
2014 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
By gene expression microarray, upon overexpression or silencing of FOXP1 in primary human B cells and DLBCL cell lines, combined with chromatin immunoprecipitation followed by next-generation sequencing, we established that FOXP1 directly represses a set of 7 proapoptotic genes.
|
25267198 |
2014 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our study revealed that non-IG rearrangements of FOXP1 are usually acquired during clinical course of various lymphoma subtypes, including diffuse large B cell lymphoma, marginal zone lymphoma and chronic lymphocytic leukemia, and correlate with a poor prognosis.
|
24416450 |
2014 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We analyzed 100 cases of DLBCL to evaluate the prognostic value of immunohistochemical markers derived from the gene expression profiling-defined cell origin signature, including MYC, BCL2, BCL6, and FOXP1 protein expression.
|
24887414 |
2014 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunophenotype expression of FoxP1 carries a poor prognosis in diffuse large B-cell lymphoma as elsewhere.
|
22368156 |
2013 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
FOXP1 overexpression is associated with poor prognosis in DLBCL, gastric MALT lymphoma and hepatocellular carcinoma but with good prognosis in breast cancer.
|
23022474 |
2013 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a panel of five antibodies against GCET1, MUM1, CD10, BCL6, and FOXP1 proteins to subclassify DLBCLs according to the recent Choi algorithm, the authors showed that the genomic profiles observed between the nodal and extranodal DLBCLs were not due to the different proportions of GCB vs ABC in the two groups.
|
21832150 |
2011 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
FOXP1 protein is expressed in normal activated B cells and overexpressed in a subset of diffuse large B-cell lymphomas, including primary cutaneous large B-cell lymphomas (PCLBCL), leg type.
|
21154235 |
2011 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Only the presence of FOXP1 protein, irrespective of its gene status, is decisive for prognosis in DLBCL.
|
20579129 |
2010 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, truncated forms of FOXP1 have been associated with a subtype of Diffuse Large B-cell Lymphoma characterised by constitutive NFkappaB activity, indicating that they may inhibit this repression.
|
19487025 |
2009 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We studied 84 cases of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP)-treated DLBCL (47 GCB, 37 ABC) with GCET1, CD10, BCL6, MUM1, FOXP1, BCL2, MTA3, and cyclin D2 immunostains, and compared different combinations of the immunostaining results with the GEP classification.
|
19706817 |
2009 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, truncated FOXP1 isoforms are preferentially overexpressed in PCNSL as they are in diffuse large B-cell lymphomas.
|
19680146 |
2009 |